scholarly journals Assessment of Brain Glucose Metabolism Following Cardiac Arrest by [18F]FDG Positron Emission Tomography

2020 ◽  
Author(s):  
Hannah J. Zhang ◽  
Samuel Mitchell ◽  
Yong-Hu Fang ◽  
Hsiu-Ming Tsai ◽  
Lin Piao ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Glucose Metabolism ◽  
Fdg Pet ◽  
Brain Metabolism ◽  
Persistent Vegetative State ◽  
Standardized Uptake Value ◽  
Brain Atlas ◽  
Fdg Uptake ◽  
Pet Ct ◽  
The Brain

AbstractBackgroundCardiac arrest (CA) patients who survived by cardiopulmonary resuscitation (CPR) can present different levels of neurological deficits ranging from minor cognitive impairments to persistent vegetative state and brain death. The pathophysiology of the resulting brain injury is poorly understood and whether changes in post-CA brain metabolism contribute to the injury are unknown. Here we utilized [18F]FDG-PET to study in vivo cerebral glucose metabolism 72 hours following CA in a murine cardiac arrest model.MethodsAnesthetized and ventilated adult C57BL/6 mice underwent 12-minute KCl-induced CA followed by CPR. Seventy-two hours following cardiac arrest, surviving mice were intraperitoneally injected with [18F]FDG (~186 μCi/200 μL) and imaged on Molecubes preclinical micro PET/CT imaging systems after a 30-minute awake uptake period. Brain [18F]FDG uptake was determined by the VivoQuant software on fused PET/CT images with the 3D brain atlas. Upon completion of PET imaging, remaining [18F]FDG radioactivity in the brain, heart, and liver was determined using a gamma counter.ResultsGlobal increases in brain [18F]FDG uptake in post-CA mice were observed compared to shams and controls. The median standardized uptake value (SUV) of [18F]FDG for CA animals was 1.79 vs. sham 1.25 (p<0.05) and control animals 0.78 (p<0.01). This increased uptake was consistent throughout the 60-minute imaging period and across all brain regions reaching statistical significance in the midbrain, pons, and medulla. Biodistribution analyses of various key organs yielded similar observations that the median [18F]FDG uptake for brain were 7.04%ID/g tissue for CA mice vs 5.537%ID/g tissue for sham animals, p<0.05).ConclusionsThis study has successfully applied [18F]FDG-PET/CT to measure changes in brain metabolism in a murine model of asystolic CA. Our results demonstrate increased [18F]FDG uptake in the brain 72 hours following CA, suggesting increased metabolic demand in the case of severe neurological injury. Further study is warranted to determine the etiology of these changes.

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5079-5079
Author(s):  
Ronald Walker ◽  
Erik Rasmussen ◽  
Laurie Jones-Jackson ◽  
Elias J. Anaissie ◽  
Terri L. Alpe ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Glucose Metabolism ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Tumor Infiltration ◽  
Imaging Studies ◽  
Fdg Uptake ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
The Brain

Abstract Introduction: Magnetic Resonance Imaging (MRI) and 18F-labeled fluorodeoxyglucose (FDG) positron emission tomography - computed tomography (PET-CT) imaging are both useful for diagnosis, staging, and restaging of multiple myeloma (MM), yet they are based on different physical principles and do not give equivalent results. It is widely known that FDG uptake can be transiently inhibited in a variety of malignancies due to recent treatment, whether transient or durable. We investigated patients from Total Therapies 2 and 3 who had baseline PET-CT exams without focal lesions (FL) at time of diagnosis that had 1 or more baseline MRI-defined FL to determine reasons for the discrepancies between imaging studies. Results: Thirty-three (33) TT2 and TT3 patients with baseline MRI-FL but without baseline PET-FL were identified. A detailed review of the clinical records and imaging studies was performed to identify potential reasons for the discrepancies between the imaging studies. One (3%) was a database error with no discrepancy. One patient (3%) had MRI-FL limited to the calvarium, an area difficult to visualize on PET-CT because of normal intense uptake in the brain. Four (12%) had “masking” of the PET FL (the PET-FL were obscured against the background by intense uptake in the surrounding marrow from severe diffuse tumor infiltration), 7 (21%) had FL seen by MRI that were below the PET resolution (sub-5mm), and 10 (30%) had PET suppression from treatment prior to arrival at our institution (glucocorticoids, such as dexamethasone or prednisone most commonly, but other medication-related causes included VDTPACE and bisphosphonates). In ten patients (30%) the causes for the discrepant imaging results were not determined, though indolent disease with low glucose metabolism resulting in poor FDG uptake relative to background is a possible explanation. Conclusion: We conclude that FDG PET-CT and MRI imaging at baseline are important and complementary examinations that do not provide equivalent results. The PET-CT can be transiently and rapidly suppressed by pretreatment with a variety of medications that can inhibit glucose metabolism. Additionally, FDG PET-CT imaging can underestimate the number of FL if there is severe, diffuse metabolically active tumor infiltration (“masking”) obscuring the margins of the PET-defined FL, if the FL are very small (sub-5mm, below FDG PET-CT resolution), if the FL are located in “blind spots” for the PET-CT scan (such as near the brain), or if the PET-CT FL are low in metabolic activity relative to normal tissue (poor FDG uptake). In some cases, no apparent reason was determined. A careful history regarding recent medication is very important for proper interpretation of the results of a sensitive functional imaging study such as FDG PET-CT, as well as an understanding of its physical limitations.

scholarly journals Pulmonary Findings of [18F]FDG PET/CT Images on Asymptomatic COVID-19 Patients

Pathogens ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 839
Author(s):  
Tzu-Chuan Ho ◽  
Chin-Chuan Chang ◽  
Hung-Pin Chan ◽  
Ying-Fong Huang ◽  
Yi-Ming Arthur Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Fdg Uptake ◽  
Asymptomatic Patients ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Maximal Standardized Uptake Value ◽  
Fdg Pet Ct

During the coronavirus disease 2019 (COVID-19) pandemic, several case studies demonstrated that many asymptomatic patients with COVID-19 underwent fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) examination for various indications. However, there is a lack of literature to characterize the pattern of [18F]FDG PET/CT imaging on asymptomatic COVID-19 patients. Therefore, a systematic review to analyze the pulmonary findings of [18F]FDG PET/CT on asymptomatic COVID-19 patients was conducted. This systematic review was performed under the guidelines of PRISMA. PubMed, Medline, and Web of Science were used to search for articles for this review. Articles with the key words: “asymptomatic”, “COVID-19”, “[18F]FDG PET/CT”, and “nuclear medicine” were searched for from 1 January 2020 to 20 May 2021. Thirty asymptomatic patients with COVID-19 were included in the eighteen articles. These patients had a mean age of 62.25 ± 14.85 years (male: 67.71 ± 12.00; female: 56.79 ± 15.81). [18F]FDG-avid lung lesions were found in 93.33% (28/30) of total patients. The major lesion was [18F]FDG-avid multiple ground-glass opacities (GGOs) in the peripheral or subpleural region in bilateral lungs, followed by the consolidation. The intensity of [18F]FDG uptake in multiple GGOs was 5.605 ± 2.914 (range from 2 to 12) for maximal standardized uptake value (SUVmax). [18F]FDG-avid thoracic lymph nodes (LN) were observed in 40% (12/40) of the patients. They mostly appeared in both mediastinal and hilar regions with an SUVmax of 5.8 ± 2.93 (range from 2.5 to 9.6). The [18F]FDG uptake was observed in multiple GGOs, as well as in the mediastinal and hilar LNs. These are common patterns in PET/CT of asymptomatic patients with COVID-19.

scholarly journals Thyroid lesions incidentally detected by 18F-FDG PET-CT ― a two centre retrospective study

2015 ◽  
Vol 49 (2) ◽  
pp. 121-127 ◽  
Author(s):  
Jan Jamsek ◽  
Ivana Zagar ◽  
Simona Gaberscek ◽  
Marko Grmek
Keyword(s):  
Fdg Pet ◽  
Malignant Lesion ◽  
Standardized Uptake Value ◽  
Benign Lesions ◽  
Fdg Uptake ◽  
Pet Ct ◽  
Thyroid Uptake ◽  
Malignant Lesions ◽  
Fdg Pet Ct ◽  
Thyroid Lesions

AbstractBackground. Incidental18F-FDG uptake in the thyroid on PET-CT examinations represents a diagnostic challenge. The maximal standardized uptake value (SUVmax) is one possible parameter that can help in distinguishing between benign and malignant thyroid PET lesions.Patients and methods. We retrospectively evaluated18F-FDG PET-CT examinations of 5,911 patients performed at two different medical centres from 2010 to 2011. If pathologically increased activity was accidentally detected in the thyroid, the SUVmaxof the thyroid lesion was calculated. Patients with incidental18F-FDG uptake in the thyroid were instructed to visit a thyroidologist, who performed further investigation including fine needle aspiration cytology (FNAC) if needed. Lesions deemed suspicious after FNAC were referred for surgery.Results. Incidental18F-FDG uptake in the thyroid was found in 3.89% ― in 230 out of 5,911 patients investigated on PET-CT. Malignant thyroid lesions (represented with focal thyroid uptake) were detected in 10 of 66 patients (in 15.2%). In the first medical centre the SUVmaxof 36 benign lesions was 5.6 ± 2.8 compared to 15.8 ± 9.2 of 5 malignant lesions (p < 0.001). In the second centre the SUVmaxof 20 benign lesions was 3.7 ± 2.2 compared to 5.1 ± 2.3 of 5 malignant lesions (p = 0.217). All 29 further investigated diffuse thyroid lesions were benign.Conclusions. Incidental18F-FDG uptake in the thyroid was found in 3.89% of patients who had a PET-CT examination. Only focal thyroid uptake represented a malignant lesion in our study ― in 15.2% of all focal thyroid lesions. SUVmaxshould only serve as one of several parameters that alert the clinician on the possibility of thyroid malignancy.

scholarly journals Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia

2021 ◽  
Vol 11 ◽  
Author(s):  
Yiping Shi ◽  
Lian Xu ◽  
Yinjie Zhu ◽  
Yining Wang ◽  
Ruohua Chen ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Pet Ct ◽  
Node Metastases ◽  
Ct Data ◽  
Fdg Pet Ct

PurposeDifferentiating lymph node metastases (LNM) from peripheral ganglia by physiological prostate-specific membrane antigen (PSMA) uptake is challenging. Two tracers (68Ga-PSMA-11 and 18F-fluorodeoxyglucose [FDG]) metabolic uptake patterns were evaluated by positron emission tomography-computed tomography (PET-CT), searching for differences that could tell ganglia from LNM.MethodsDual 68Ga-PSMA-11 and 18F-FDG PET-CT data of 138 prostate cancer patients acquired from June 2018 to December 2019 were retrospectively evaluated. Ganglia and LNM with PSMA-11 uptake above local background were analyzed by the location and PSMA-11-PET and FDG-PET maximum standardized uptake value (SUVmax).ResultsPSMA-11-positive ganglia (n = 381) and LNM (n = 83) were identified in 138 and 58 patients, respectively. The LNM SUVmax of PSMA-11-PET (16.4 ± 14.8 vs 2.3 ± 0.7, P &lt; 0.001) and FDG-PET (3.3 ± 3.2 vs 1.5 ± 0.5, P &lt; 0.001) were higher than in ganglia. The probabilities of being an LNM in the low-potential (PSMA-11-PET SUVmax of &lt;4.1 and FDG-PET SUVmax of &lt;2.05), moderate-potential (PSMA-11-PET SUVmax of &gt;4.1 and FDG-PET SUVmax of &lt;2.05, or PSMA-11-PET SUVmax of &lt;4.1 and FDG-PET SUVmax of &gt;2.05), and high-potential (PSMA-11-PET SUVmax of &gt;4.1 and FDG-PET SUVmax of &gt;2.05) groups were 0.9% (3/334), 44.6% (37/83), and 91.5% (43/47), respectively (P &lt; 0.001). The cervical and coeliac ganglia had higher PSMA-11 and FDG uptake than the sacral ganglia (P &lt; 0.001 for all). LNM PSMA-11 and FDG uptake was similar in these three locations.ConclusionThe FDG-PET and PSMA-11-PET SUVmax, especially when combined, could well differentiate LNM from ganglia. The tracers uptake differed between cervical/coeliac and sacral ganglia, so the lesion location should be considered during image assessment.

scholarly journals Lateralized periodic discharges frequency correlates with glucose metabolism

Neurology ◽  
2019 ◽  
Vol 92 (7) ◽  
pp. e670-e674 ◽  
Author(s):  
Thanujaa Subramaniam ◽  
Aditya Jain ◽  
Lance T. Hall ◽  
Andrew J. Cole ◽  
M. Brandon Westover ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Fdg Pet ◽  
Medical Records ◽  
Standardized Uptake Value ◽  
Continuous Variable ◽  
Continuous Measure ◽  
Categorical Variable ◽  
Fdg Uptake ◽  
Periodic Discharges ◽  
Structural Lesion

ObjectiveTo investigate the correlation between characteristics of lateralized periodic discharges (LPDs) and glucose metabolism measured by 18F-fluorodeoxyglucose (FDG)–PET.MethodsWe retrospectively reviewed medical records to identify patients who underwent FDG-PET during EEG monitoring with LPDs present during the FDG uptake period. Two blinded board-certified neurophysiologists independently interpreted EEGs. FDG uptake was measured using standardized uptake value (SUV). Structural images were fused with PET images to aid with localization of SUV. Two PET readers independently measured maximum SUV. Relative SUV values were obtained by normalization of the maximum SUV to the SUV of pons (SUVRpons). LPD frequency was analyzed both as a categorical variable and as a continuous measure. Other secondary variables included duration, amplitude, presence of structural lesion, and “plus” EEG features such as rhythmic or fast sharp activity.ResultsNine patients were identified and 7 had a structural etiology for LPDs. Analysis using frequency as a categorical variable and continuous variable showed an association between increased LPD frequency and increased ipsilateral SUVRpons (p = 0.02). Metabolism associated with LPDs (0.5 Hz as a baseline) increased by a median of 100% at 1 Hz and for frequencies >1 Hz increased by a median of 309%. There were no statistically significant differences in SUVRpons for other factors including duration (p = 0.10), amplitude (p = 0.80), structural etiology (p = 0.55), or “plus” features such as rhythmic or fast sharp activity (p = 0.84).ConclusionsMetabolic activity increases monotonically with LPD frequency. LPD frequency should be a measure of interest when developing neuroprotection strategies in critical neurologic illness.

scholarly journals The clinical impact of incidental sellar uptake on F-18 FDG PET/CT

2019 ◽  
Vol 6 (2) ◽  
pp. IJE15
Author(s):  
Zehra Pınar Koç ◽  
Pelin Özcan Kara ◽  
Emel Sezer ◽  
Kadir Eser ◽  
Anıl Özgür
Keyword(s):  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Sellar Region ◽  
Primary Tumors ◽  
Fdg Uptake ◽  
Pet Ct ◽  
Frequent Finding ◽  
Metastatic Involvement ◽  
Fdg Pet Ct

Aim: The most frequent finding associated with incidental fluorodeoxyglucose (FDG) uptake in sellar region in oncologic F-18 FDG PET/CT is adenoma. However, reports of metastatic involvement exist. We investigated the clinical significance of incidental FDG uptake in this region. Materials & method: 34 patients with several primary tumors who were referred for staging, restaging or treatment response via F-18 FDG PET/CT were included. Images were reviewed and patients with significant FDG uptake in the sellar region were referred. Results: Mean lesion diameter was 11.9 ± 4.9 mm and mean standardized uptake value was 8.2 ± 6.1. Thirteen patients underwent MRI, and the others underwent follow-up F-18 FDG PET/CT. MRI revealed metastatic involvement in nine patients and macro- or micro-adenoma in four. Metastatic patients also had other lesions, yet management did not change. Conclusion: FDG accumulation in the sellar region might be associated with metastasis or adenoma. However, it did not change management. Future studies are warranted.

scholarly journals The role of 18-FDG PET/CT assessment of functional brain metabolism in cancer patients after chemotherapy

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Shady Mohamed Tarek Gamal ◽  
Amr Osama M. A. Azab ◽  
Sherif Mohamed El Refaei ◽  
Mohamed Houseni
Keyword(s):  
Glucose Uptake ◽  
Cancer Patients ◽  
Brain Metabolism ◽  
Imaging Techniques ◽  
Ct Scans ◽  
Fdg Uptake ◽  
Speed Of Information Processing ◽  
Pet Ct ◽  
The Brain

Abstract Background Most neuropsychological studies on chemotherapy (CHT)-treated cancer survivors reported cognitive impairments in multiple domains such as executive functions, learning, memory, attention, verbal fluency, and speed of information processing. The CHT effects range from small to moderate, involving mostly the cognitive functions sub-served by frontal lobe. This study aimed to evaluate the role of PET/CT in the assessment of the effect of chemotherapy on the glucose metabolism in the brain in cancer patients after the chemotherapy treatment. Results This was a prospective study carried out in 2 years for patients who have done PET/CT scans for assessment of the change of the glucose uptake in the brain in pre- and in post-therapeutic state. A total number of 30 patients, 8 males and 22 females, were examined. The age of the patients ranged from 29 to 79 years (mean 57.9). Each patient underwent at least two PET/CT scans, first before the initiation of the therapy, and second was at least 3 months after starting the chemotherapy regimen. This study employed an adaptive threshold method, SCENIUM version 2.0.1. Automatic ROI identification was performed through around 10 regions of the brain. After segmentation of FDG uptake in the different brain regions of each subject, we measured average glucose uptake (SUVmean), registered by SCENIUM software. Conclusion There was significant reduction in the brain metabolism “FDG uptake” in all regions of the brain, mainly at the mesial temporal lobes as well as the frontal lobes. This metabolic change proves that chemotherapy has an adverse effect on the brain that can be objectively assessed with modern imaging techniques.

scholarly journals What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Priya Bhosale ◽  
Aparna Balachandran ◽  
Raghu Vikram ◽  
Chitra Viswanathan ◽  
Homer Macapinlac ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Prostate Carcinoma ◽  
Fdg Pet ◽  
Prostate Gland ◽  
Elevated Serum ◽  
Standardized Uptake Value ◽  
Prior History ◽  
Fdg Uptake ◽  
Pet Ct ◽  
Fdg Pet Ct

Purpose. To determine the clinical significance of unexpected, abnormal FDG uptake in the prostate in patients undergoing FDG-PET/CT for staging of other primary malignancies without a prior history of prostate carcinoma. Methods. Retrospective search of FDG-PET/CT studies to identify patients with unexpected, abnormal FDG uptake in the prostate gland, who underwent subsequent biopsy, was performed. 26 patients were identified. Images were reviewed to determine the pattern of uptake within the prostate (focal or diffuse) and maximum standardized uptake value (SUVmax). PSA and Gleason scores were recorded. Results. 15/26 (58%) patients were found to have prostate carcinoma. Gleason scores ranged from 6 to 9.9. There was no statistical difference in the pattern of uptake (focal versus diffuse) or the SUVmax. Serum PSA levels with cancer (range, 2–26.8 ng; mean, 10.2 ng) and those without cancer (range, 2–10.5 ng; mean, 2.2 ng) were statistically significant (P<0.007, Wilcoxon rank sum test). Conclusions. Patients with abnormal uptake in the prostate have a 58% likelihood of occult prostate cancer. In the setting of elevated serum PSA levels, abnormal prostate uptake should therefore be viewed with suspicion and a urology consult should be obtained; however, it is irrelevant in patients with underlying aggressive malignancies.

scholarly journals Early post-ischemic glucose metabolism is dependent on function of TLR2: a study using [18F]FDG PET-CT in a mouse model of cardiac arrest and cardiopulmonary resuscitation

2021 ◽  
Author(s):  
Rika Bajorat ◽  
Jens Kurth ◽  
Jan Stenzel ◽  
Brigitte Vollmar ◽  
Bernd J. Krause ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Glucose Metabolism ◽  
Cardiopulmonary Resuscitation ◽  
Mouse Model ◽  
Fdg Pet ◽  
Mouse Strains ◽  
Whole Brain ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose: An ischemic brain injury caused by cardiac arrest (CA) and cardiopulmonary resuscitation (CPR) affects cerebral function and presumably also brain glucose metabolism. The majority of patients who survive CA suffer from cognitive deficits and physical disabilities. Toll-like receptor 2 (TLR2) plays a cruical role in inflammatory response in ischemia and reperfusion (I/R). Since deficiency of TLR2 was associated with increased survival after CA-CPR, in this study glucose metabolism was measured using non-invasive [18F]FDG PET-CT imaging before and early after CA-CPR in a mouse model comparing wild type (WT) and TLR2-deficient (TLR2-/-) mice. Methods: Two PET-CT scans using [18F]FDG tracer were carried out to measure dynamic glucose metabolism before and early after CPR. To achieve this, anesthetized and ventilated adult female WT and TLR2-/- mice were scanned in PET-CT. After recovery from the baseline scan, the same animals underwent 10-minute CA followed by CPR and approximately 90 min after CA measurements of [18F]FDG uptake were started. The [18F]FDG standardized uptake values (SUVs) were calculated using PMOD-Software on fused FDG-PET-CT images with the included 3D Mirrione-Mouse-Brain-Atlas. Results: The absolute SUV of glucose in the whole brain of WT mice was increased after CA-CPR. In contrast, the absolute glucose SUV in the whole brain of TLR2-/- mice was not significantly different between basal and measurements after CA-CPR. In comparison, basal measurements of both mouse strains show a significant difference in the whole brain absolute glucose SUVs, whereby TLR2-/- mice revealed 34.6% higher values. The altered mouse strains presented a different pattern in glucose uptake under normal and ischemic conditions. Conclusion: There is evidence that the post-ischemic differences in glucose metabolism were associated with the function of TLR2 and that PET-CT imaging could be useful as an additional methodology in assessing diagnosis and prognosis during post-cardiac arrest care. Further studies are needed.

scholarly journals Role of PET-CT in Aiding Diagnosis of Various Neurological Conditions – A Case Series

2021 ◽  
Vol 10 (7) ◽  
pp. 440-446
Author(s):  
Harleen Singh Pabla ◽  
Gokulakrishnan P.R. ◽  
Arunan Murali ◽  
Venkata Sai P.M.
Keyword(s):  
Metabolic Activity ◽  
Fdg Pet ◽  
Caudate Nuclei ◽  
Fdg Uptake ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Neurological Conditions ◽  
Fdg Pet Ct ◽  
The Brain

BACKGROUND PET-CT is an imaging modality which electronically detects positron-emitting radiopharmaceuticals in the human body and reveals its exact anatomical location.1 PET CT measures the metabolic and functional activity of living tissue noninvasively.1 This technology is utilized in diagnosis, planning treatment and predicting outcomes in various neurological conditions.1 Depending upon various patterns of FDG uptake in different parts of brain, 18FDG PET-CT allows us to differentiate between various types of dementia.2 PET CT allows tracking the course of disease and revealing the severity of the disease.2 In this article, we discuss the imaging findings of normal 18 FDG PET-CT of brain and 8 different neurological conditions with their corresponding brain PET-CT findings. METHODS To study the role of 18FDG-PET/CT in neurological conditions, we identified 8 different patients who underwent 18FDG-PET/CT imaging of brain for clinically suspected different neurological diseases at Department of Radiodiagnosis-Centre of Excellence (CERIS), SRIHER, Chennai, between 2015 and 2019. Siemens Biograph Horizon 16-slice PET/CT scanner with TrueV was used. Syngo.Via Version VB30A software was used. 18F- Fluorodeoxyglucose was the radiotracer used [Dose: 3-7 mCi]. After the scan, different patterns of 18 FDG uptake in the brain were analyzed in each of these patients. RESULTS 18 FDG PET-CT showed reduced uptake in the epileptogenic foci in the brain. Alzheimer’s disease showed decreased FDG uptake in bilateral precuneus, posterior cingulate region, parietal cortex and frontal cortex. Fronto-temporal dementia revealed reduced FDG uptake in anterior cingulate gyrus and anterior temporal lobe. Primary progressive aphasia showed asymmetrical reduced metabolic activity in the bilateral frontal and temporal lobes. Progressive supranuclear palsy revealed reduced metabolic activity in bilateral paramedian frontal region, head of caudate nuclei and midbrain; Multi systemic atrophy showed reduced metabolic activity in midbrain, pons, medulla oblongata and the cerebellum; AIDS related dementia showed global hypometabolism with preserved uptake in basal ganglia. CONCLUSIONS 18FDG-PET/CT has a vital complementary role in the evaluation CNS disorders along with clinical examination, other imaging modalities like CT, MRI, and electroencephalogram (EEG). Radiologists should be aware of these different patterns of FDG uptake to aid the clinical diagnosis and early treatment. KEY WORDS 18 FDG PET-CT, 18FDG Uptake, Hypometabolism, PET-CT Brain

Sign in / Sign up

Export Citation Format

Share Document